key: cord-0257303-456d4eiu
authors: Worku, E. T.; Brodie, D.; Ling, R. R.; Ramanathan, K.; Combes, A.; Shekar, K.
title: Venovenous Extracorporeal CO2 removal to support ultraprotective ventilation in moderate-severe ARDS: A systematic review and meta-analysis of the literature
date: 2021-10-27
journal: nan
DOI: 10.1101/2021.10.26.21265546
sha: e79272018482b6992ab253a0f966900f70786c7a
doc_id: 257303
cord_uid: 456d4eiu

A strategy that limits tidal volumes and inspiratory pressures, improves outcomes in patients with the acute respiratory distress syndrome (ARDS). Extracorporeal carbon dioxide removal (ECCO2R) may facilitate ultra-protective ventilation . We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of venovenous ECCO2R in supporting ultra-protective ventilation in moderate-to-severe ARDS. Methods: MEDLINE and EMBASE were interrogated for studies (2000-2021) reporting venovenous ECCO2R use in patients with moderate-to-severe ARDS. Studies reporting [≥]10 adult patients in English language journals were included. Ventilatory parameters after 24 hours of initiating ECCO2R, device characteristics, and safety outcomes were collected. The primary outcome measure was the change in driving pressure at 24 hours of ECCO2R therapy in relation to baseline. Secondary outcomes included change in tidal volume, gas exchange, and safety data. Results: Ten studies reporting 421 patients (PaO2:FiO2 141.03mmHg) were included. Extracorporeal blood flow rates ranged from 0.35-1.5 L/min. Random effects modelling indicated a 3.56 cmH2O reduction (95%-CI: 3.22-3.91) in driving pressure from baseline (p<0.001) and a 1.89 ml/kg (95%-CI: 1.75-2.02, p<0.001) reduction in tidal volume. Oxygenation, respiratory rate and PEEP remained unchanged. No significant interactions between driving pressure reduction and baseline driving pressure, partial pressure of arterial carbon dioxide or PaO2:FiO2 ratio were identified in metaregression analysis. Bleeding and haemolysis were the commonest complications of therapy. Conclusions: Venovenous ECCO2R permitted significant reductions in {Delta}P in patients with moderateto- severe ARDS. Heterogeneity amongst studies and devices, a paucity of randomised controlled trials, and variable safety reporting calls for standardisation of outcome reporting. Prospective evaluation of optimal device operation and anticoagulation in high quality studies is required before further recommendations can be made.

Freeman-Tukey double arcsine transformation, and computed the 95% confidence intervals (CIs) using the Clopper-Pearson method. [40] [41] [42] Sensitivity analyses were conducted by simulating different values of r, including 0, 0.25, 0.75 and 0.9. A second sensitivity analysis was conducted by excluding studies with relatively higher risks of bias (defined a priori as JBI score <8). As interstudy heterogeneity among observational studies can be misleadingly overestimated when using I 2 statistics, we used the GRADE approach to assess the interstudy variability 43 . Meta-regression analyses were conducted if a minimum of 6 data points could be collected, in accordance with previous meta-analyses, 43 to explore potentially prognostically relevant study-level covariates and possible sources of heterogeneity (supplement), for example the influence of baseline driving pressure on the primary outcome under ECCO 2 R. Statistical analyses were performed on R3.6.2.

Of 534 citations identified, 346 were reviewed at the abstract level, and 23 as full texts. In total, ten studies, reporting 421 patients, were identified spanning October 2009 44 through August 2021 45 (PRISMA figure -supplement). There were 2 prospective pilot studies, 4 prospective observational cohort studies, 1 retrospective chart review, 1 prospective multicentre international phase 2 study, 1 quasi-experimental prospective observational cohort study, and 1 randomised controlled trial (RCT) (table 1). Baseline patient demographraphics were broadly homogenous (table1, and supplement) with a preponderance of men (68.4%), and mean age 62.2 years. Baseline PaO 2 :FiO 2 ratios ranged from ; two studies 46 47 included mixed indications for ECCO 2 R therapy (e.g. acute hypercapnic exacerbations of chronic obstructive disease), but ARDS specific data was able to be extracted. In one study, mean Vt at inclusion was slightly above the average at 6.9ml/Kg PBW and was reduced more modestly to <6ml/Kg 48 , with the primary intent of maintaining PaCO 2 ( Table 2 ). All studies reported pumped venovenous devices, predominantly coupled with double-lumen catheters inserted into the internal jugular vein. Venous access generally ranged from 13Fr-15Fr in size, with larger 24Fr catheters coupled with higher blood flow rates in one trial 49 . Mean extracorporeal blood flows ranged from 350 ml.min-1 to a maximum of 970 ml.min-1 (supplement). Further appraisal of commercially available ECCO 2 R devices, qualities and operational characteristics is provided in the supplement.

The results of the meta-analysis assuming an r-value of 0.5 are presented here; the results of the other analyses with different r-values can be found in table (4) . With random effects modelling, the pooled reduction in (table 3a) . Meta-regression analysis found that increasing age was associated with smaller reductions in ∆ P (regression coefficient: 0.13, 95%CI: 0.02 to 0.24, p=0.020), but there were no other significant interactions between demographics, baseline ∆ P, PaCO 2 , and PaO 2 :FiO 2 ratio on the primary outcome of ECCO 2 R-facilitated reductions in ∆ P (see supplement).The overall pooled 28-day mortality in the cohort was 41.6% (95%CI 30.0%-53.5%) (supplement).

The mechanical, and patient-related complications of venovenous ECCO 2 R are summarised in Table   4 , with expansion in the supplementary materials. Importantly, not all studies documented all complications. Anticoagulation strategies varied, with 4 studies utilising activated partial thromboplastin time/ratio, 2 studies recording activated clotting time, and 3 adjusting to anti-factor Xa levels; in the most recent study, the intensity of anticoagulation was not reported. Bleeding rates where reported, ranged 10-50% (5/10 studies), with clinically significant bleeding rates -variably defined by transfusion requirement and validated tools (see table 4 ) -between 6 and 50%.

Intracranial haemorrhage was reported in 5 studies 45-47 49 50 at a rate of between 1 and 5%;.

Mechanical complications included catheter dislodgement, kinking or thrombosis ranging 4-40% (6/10 studies), with 2 trials reporting catheter-related infections, n=3. 46 49 Circuit thrombosis was documented in 7 studies ranging from 14-30%, leading to circuit changes in up to 6% of cases in one series. Air was noted in 2 extracorporeal circuits in one study, 46 without clinically apparent air embolism.

To our knowledge, this is the first systematic review evaluating venovenous ECCO 2 R in moderate-tosevere ARDS. Two contemporary systematic reviews assessed mixed cohorts of both chronic obstructive pulmonary disease and ARDS patients, 30 or included pumpless arteriovenous devices; 51 neither evaluated the larger venovenous ECCO 2 R study published by Combes et al 49 or the recently published "pRotective veEtilation with venovenouS lung assisT in respiratory failure (REST)" trial 45 .

Our main finding was a significant 3.56cmH 2 0 reduction in driving pressure at 24 hours. Ventilatory parameters under ECCO 2 R largely conformed with ultra-protective ventilation targets from a mechanical perspective (driving and plateau pressures) 52 . Plateau pressure was ≥ 25cmH 2 0 in all 10 cohorts at the outset, and was reduced significantly at 24 hours with reported values ≤ 25cmH 2 0 in 7 studies. Driving pressure was >14cmH 2 0 in just two of the seven studies reporting ∆ P at baseline.

While it was reduced to <10cmH 2 0 in 5 studies, and below 14cmH 2 0 in all reporting studies, tidal volume remained slightly above 4ml/Kg in the majority (table 2) . This suggests that studies reported patients with relatively preserved respiratory compliance, in whom ECCO 2 R may not be maximally efficacious. 53 54 Whether progressive reductions in driving pressure below conventionally accepted limits of ultraprotective targets can further improve patient centred outcomes compared with standard lowvolume, low-pressure ventilation strategies 6 7 21 55 56 is not entirely clear. A recent large RCT comparing conventional low tidal volumes with ECCO 2 R-enabled ultraprotective ventilation found no difference in 28-day mortality, a longer duration of mechanical ventilation and ICU length of stay (LOS) and a 31% rate of serious adverse events in the intervention group 45 . Patients with moderate-tosevere ARDS are a heterogenous cohort with emerging clinical sub-phenotypes, 57 58 thus the absence All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 27, 2021. ;  of mortality benefit in two recent RCTs is unsurprising. 45 59 Our analysis showed a pooled 28-day mortality was 41.6% (95%CI: 30.0%-53.5%), which is similar to that reported in a large metaanalysis of mechanically ventilated ARDS patients of comparable severity. 9 The lack of prospective comparison limits inferences, but the similar mortality rates, may indicate an inability of ECCO 2 R to meaningfully attenuate mechanical power, perhaps through underappreciated influences of respiratory frequency and PEEP. 10 55 60 Reductions in ventilatory frequency may represent a key target in limiting VILI. Expert opinion suggests that ECCO 2 R ultra-protective ventilation should be used to effect a respiratory rate <25 breaths per minute 52 . Greater reductions in ventilator frequency may have been demonstrated if investigators had specifically targeted greater this, had been more permissive of hypercapnia, or if the devices that were used could either achieve higher blood flow rates or greater CO 2 removal efficiency.

The median pH was >7.3 in nine of ten studies at 24hrs (table 2), however it is pertinent that the median PaCO 2 at 24hrs remained ≥ 50mmHg in 7 of the nine included studies, and greater than 55mmHg in one (pH 7.29). The absolute degree of hypercapnia tolerated must not only consider in terms of acid-base, but also right ventricular performance. 50 Interestingly, reductions in plateau pressure after ECCO 2 R initiation, rather than change in PaCO 2 were best correlated with improvements in right ventricular afterload. 50 Baseline PaCO 2 (a surrogate for the underlying dead space fraction) has previously been suggested to predict patients in whom ECCO 2 R could be most efficacious, 53 54 however this was not evident in the current metaregression analysis, nor was an interaction with severity of ARDS by oxygenation. As lower flow ECCO 2 R devices only permit partial correction of PaCO 2 , sedation and neuromuscular blocking agents may be needed to play a role in modulating patients' respiratory drive and ventilator asynchronies. [61] [62] [63] Prone positioning (PP) may be synergistic with ECCO 2 R, through enhanced reductions in driving pressure, 53 54 64 CO 2 elimination 65 66 , and right ventricular unloading 67 .While prone positioning was infrequently employed in the reported ECCO 2 R studies (n=22), it was undertaken, when used, without serious incident (table 1). All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 27, 2021. ;  A trend towards lower thrombosis and bleeding rates was seen in more recent studies, corroborating existing insights. 51 Two studies from 2016, and 2017 described 46.7% and 50% bleeding rates respectively, while the five papers from 2018-2021 recorded 10-24.3% bleeding rates. Anti-Xaguided anticoagulation may offer favourable bleeding profiles, 68 however, this could not be statistically evaluated here and definitions of bleeding were not standardised. Higher blood flow rate devices were associated with reduced haemorrhage and haemolysis (21% vs 6%, p=0.045) and (27% vs 6%, p=0.01) respectively in SUPERNOVA, 69 and the same inverse relationship -bleeding: (30% vs 6%, p=0.04), and haemolysis: (28% vs 0% ,p=0.03) 46 49 were documented by Augy et al. 46 Rotary pumps may exert increased blood trauma at lower blood flows (particularly<1L.min-1), 70-72 causing shear stress and loss of high molecular weight von Willebrand factor multimers. [73] [74] [75] [76] Mean blood flow rates may not only influence hematologic complications, but also the degree of lung protection achievable; 25 26 unfortunately several studies utilised a variety of devices and different blood flow rates, such that metaregression analysis was not appropriate. While anticoagulation management is extrapolated from the ECMO experience, perhaps personalised approaches based on device and patient characteristics, even including regional methods of anticoagulation 77 may enhance ECCO 2 R safety. 51 78 

Strengths of this review include the comprehensive search, broad criteria including available RCT data, and relevant exclusion criteria. Rigorous quality assessment was performed, deeming studies of high quality and suitable for inclusion. Furthermore, we limited the inclusion of studies to moderateto-severe ARDS which was undertaken in order to homogenise the study population, and metaregression analyses were specifically performed to interrogate whether ECCO 2 R efficacy was influenced with respect to baseline PaCO 2 , as a surrogate of dead space fraction, 53 54 66 although no such relationship was identified. Where possible, duplication of data was avoided, however 4 patients were concurrently enrolled in more than one of the reported studies; a lack of patient-level data precluded their identification and removal. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 27, 2021. ;

We nonetheless recognise several limitations of our review. Only 10 studies qualified for analysis, of which, just one was an RCT. Over 75% of the patient data was contributed by just 3 studies, with the largest study responsible for nearly half. In the aforementioned study, 50 centres were involved, thus enrolment may have been as low as 4 patients per centre. The other two manuscripts were from highly experienced ECMO centres, which may have influenced their low mortality rates (supplement). A volume-outcome effect 78 cannot be discounted. In addition, given that these studies were mostly observational, the effect estimates are open to confounding factors, particularly in the absence of propensity-score or risk-adjustment methods. Some of these include the ventilatory mode employed, right ventricular function, and other adjuvant therapies (e.g proning), with variability potentially accounting for some of the herteogeneity in observed mortalty rates (15-47%). The meta-regression analysis is limited by a small sample size (6 studies minimum), and open to Type II errors.

Further dividing the moderate-to-severe ARDS category into patients with a PaO 2 FiO 2 ratio above and below 150mmHg, 79 80 or even more directly, by dead space fraction and compliance, 53 54 81 may enhance selection. Aside from survival, there is glaring need to prospectively investigate cost effectiveness of therapy, 82 and other patient-centred outcomes such as length of hospital stay, delirium, return to premorbid function and long-term outcomes, which were inconsistently reported if at all. A suite of therapies combining ECCO 2 R of adequate intensity with prone ventilation (to perhaps enhance both lung and right ventricular protection) 66 67 83 , early spontaneous breathing 84 and mobilisation may be required to effect a meaningful survival benefit. Even in light of recent evidence, the question of whether venovenous ECCO 2 R has the power to impact mortality in the moderate-tosevere ARDS cohort still remains.

Venovenous ECCO 2 R supported significant reductions in driving pressure at 24 hours in moderate-tosevere ARDS, with an overall mortality of 41.6%. While early ECCO 2 R may facilitate ultraprotective ventilation and mitigate ARDS progression, the benefits are currently offset by the All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 27, 2021. ;  invasiveness of therapy, and limited CO 2 removal made possible at low blood flow rates. Significant reductions in respiratory rate, and hence further reductions in mechanical power may not be feasible when using very low blood flow rates, potentially limiting the utility of ECCO 2 R in patients with more severe forms of ARDS, or right ventricular dysfunction. Enrichment of study populations, and reporting data consistently to minimum standards, is critical to meaningfully researching benefits of ECCO 2 R therapy in ARDS.

Extracorporeal Life Support Organization (ELSO). AC reports receiving grants and personal fees from Maquet, Xenios and Baxter and serving as a member of the executive and scientific committees for ECMONet and as the recent past president of the EuroELSO organization. KS is a member of the ECMONet scientific committee, the Asia-Pacific ELSO educational committee, and Australia and New Zealand's Intensive Care Society COVID-19 working group; he is also the lead of an ECMOed research working group.

The search strategy and further data analysis is available in the supplementary materials 39. Higgins J, Li T, Deeks J. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Explanations a. There was significant heterogeneity, and visual inspection of the forest plots found that the point estimates were rather sparsely distributed; confidence intervals occasionally overlapped. b. While the 95%-CI remains relatively narrow with respect to the pooled estimate, the sample size is small and below the optimal information size. As such, we downgraded for imprecision . S  t  u  d  y  N  =  B  l  e  e  d  i  n  g  S  i  g  n  i  f  i  c  a  n  t  H  a  e  m  o  l  y  s  i  s  C  a  t  h  e  t  e  r  C  o  m  p  l  i  c  a  t  i  o  n   C  i  r  c  u  i  t  C  l  o  t  t  i  n  g  C  i  r  c  u  i  t  m  a  l  f  u  n  c  t  i  o  n   I  C  H  /  S  A  E   M  c  N  a  m  e  e  2  0  2  1   2  0  2  1  8  (  8  .  9  %  )  n  o  n  -I  C  H  b  l  e  e  d  s   O  f  w  h  i  c  h  8  (  4  %  )  c  a  n  n  u  l  a  r  e  l  a  t  e  d   6  n  o  n  -I  C  H  b  l  e  e  d  s  r  e  p  o  r  t  e  d  a 

Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries

Causes and timing of death in patients with ARDS

Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome

Protective mechanical ventilation in the non-injured lung: review and meta-analysis

Driving pressure and survival in the acute respiratory distress syndrome

Driving pressure: a marker of severity, a safety limit, or a goal for mechanical ventilation?

Associations between ventilator settings during extracorporeal membrane oxygenation for refractory hypoxemia and outcome in patients with acute respiratory distress syndrome: a pooled individual patient data analysis : Mechanical ventilation during ECMO

Mechanical Power, and 3-Year Outcomes in Acute Respiratory Distress Syndrome Patients Using Standardized Screening. An Observational Cohort Study

Association of Driving Pressure With Mortality Among Ventilated Patients With Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis

Ventilator-related causes of lung injury: the mechanical power

Dynamic predictors of VILI risk: beyond the driving pressure

Role of Strain Rate in the Pathogenesis of Ventilator-Induced Lung Edema

Feasibility and safety of ultra-low tidal volume ventilation without extracorporeal circulation in moderately severe and severe ARDS patients

Hypercapnia: a nonpermissive environment for the lung

Hypercapnia and acidosis in sepsis: a double-edged sword?

Acute cor pulmonale during protective ventilation for acute respiratory distress syndrome: prevalence, predictors, and clinical impact

Bench to bedside review: Extracorporeal carbon dioxide removal, past present and future

When the momentum has gone: what will be the role of extracorporeal lung support in the future?

Identification of determinants required for agonistic and inverse agonistic ligand properties at the ADP receptor P2Y12

Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome

Near-Apneic Ventilation Decreases Lung Injury and Fibroproliferation in an Acute Respiratory Distress Syndrome Model with Extracorporeal Membrane Oxygenation

Physiological Basis of Extracorporeal Membrane Oxygenation and Extracorporeal Carbon Dioxide Removal in Respiratory Failure

Clinical review: Extracorporeal membrane oxygenation

Blood oxygenation and decarboxylation determinants during venovenous ECMO for respiratory failure in adults

Impact of membrane lung surface area and blood flow on extracorporeal CO2 removal during severe respiratory acidosis

Impact of sweep gas flow on extracorporeal CO2 removal (ECCO2R)

Use of extracorporeal carbon dioxide removal (ECCO2R) in 239 intensive care units: results from a French national survey

Low-frequency positive pressure ventilation with extracorporeal carbon dioxide removal (LFPPV-ECCO2R): an experimental study

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

Extracorporeal CO2 removal in critically ill patients: a systematic review

ECMO for severe ARDS: systematic review and individual patient data metaanalysis

The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination

Acute respiratory distress syndrome: the Berlin Definition

Extracorporeal pumpless interventional lung assist in clinical practice: determinants of efficacy

A novel pump-driven veno-venous gas exchange system during extracorporeal CO2-removal

Bridge to lung transplantation with the novel pumpless interventional lung assist device NovaLung

A new pumpless extracorporeal interventional lung assist in critical hypoxemia/hypercapnia

Validity of the lipid sink as a mechanism for the reversal of local anesthetic systemic toxicity: a physiologically based pharmacokinetic model study

Respiratory drive in the acute respiratory distress syndrome: pathophysiology, monitoring, and therapeutic interventions

Respiratory Drive in Critically Ill Patients. Pathophysiology and Clinical Implications

Prone positioning monitored by electrical impedance tomography in patients with severe acute respiratory distress syndrome on veno-venous ECMO

PaCO2 and alveolar dead space are more relevant than PaO2/FiO2 ratio in monitoring the respiratory response to prone position in ARDS patients: a physiological study

Decrease in PaCO2 with prone position is predictive of improved outcome in acute respiratory distress syndrome

Prone positioning unloads the right ventricle in severe ARDS

Conversion From Activated Clotting Time to Anti-Xa Heparin Activity Assay for Heparin Monitoring During Extracorporeal Membrane Oxygenation

Efficacy and safety of lower versus higher CO2 extraction devices to allow ultraprotective ventilation: secondary analysis of the SUPERNOVA study

Low flow rate alters haemostatic parameters in an ex-vivo extracorporeal membrane oxygenation circuit

Shear-induced unfolding triggers adhesion of von Willebrand factor fibers

Low-flow assessment of current ECMO/ECCO2R rotary blood pumps and the potential effect on hemocompatibility

Acquired von Willebrand syndrome in patients with ventricular assist device or total artificial heart

Acquired von Willebrand syndrome in patients with extracorporeal life support (ECLS)

Acquired Von Willebrand syndrome in patients on long-term support with HeartMate II

Computational fluid dynamics analysis of blade tip clearances on hemodynamic performance and blood damage in a centrifugal ventricular assist device

Extracorporeal CO2 removal and regional citrate anticoagulation in an experimental model of hypercapnic acidosis

Association of hospital-level volume of extracorporeal membrane oxygenation cases and mortality. Analysis of the extracorporeal life support organization registry

Reclassifying Acute Respiratory Distress Syndrome

Severe hypoxemia: which strategy to choose

Effect of Lowering Tidal Volume on Mortality in ARDS Varies with Respiratory System Elastance

A preliminary cost-effectiveness analysis of lung protective ventilation with extra corporeal carbon dioxide removal (ECCO2R) in the management of acute respiratory distress syndrome (ARDS)

Prone positioning during venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-analysis

Extracorporeal Membrane Oxygenation for Patients With COVID-19 in Severe Respiratory Failure

The